Advertisement

Topics

Phase III NAVIGATE ESUS study of Xarelto stopped early due to comparable efficacy in treatment arms

17:56 EDT 8 Oct 2017 | PharmaBiz

Janssen Research & Development, LLC and its development partner Bayer have announced the phase III NAVIGATE ESUS study, evaluating the efficacy and safety of Xarelto (rivaroxaban) for the secondary

Original Article: Phase III NAVIGATE ESUS study of Xarelto stopped early due to comparable efficacy in treatment arms

NEXT ARTICLE

More From BioPortfolio on "Phase III NAVIGATE ESUS study of Xarelto stopped early due to comparable efficacy in treatment arms"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...